Abiopharma

New Form 8-K - Akebia Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001517022-25-000034 Size: 264 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Monte Rosa Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104550 Size: 10 MB

New Form 8-K - Phathom Pharmaceuticals, Inc. Filed: 2025-08-07 AccNo: 0001193125-25-174943 Size: 237 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Phathom Pharmaceuticals, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104548 Size: 10 MB

New Form 8-K - Cartesian Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001453687-25-000098 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 6-K - GH Research PLC Filed: 2025-08-07 AccNo: 0001140361-25-029344 Size: 4 MB

New Form 8-K - ELI LILLY & Co Filed: 2025-08-07 AccNo: 0000059478-25-000202 Size: 500 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - C4 Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001628280-25-038576 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Ironwood - Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

New Form 8-K - LIGAND PHARMACEUTICALS INC Filed: 2025-08-07 AccNo: 0000886163-25-000047 Size: 399 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Cullinan Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104547 Size: 398 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Black Diamond Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001701541-25-000030 Size: 5 MB

New Form 10-Q - Avalo Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001628280-25-038575 Size: 7 MB

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call